Novo Nordisk A/S Stock Forecast for 2023 - 2025 - 2030
Updated on 09/25/2023
Novo Nordisk A/S Stock Forecast and Price Target
If the average price target of kr975.00 set by sixteen distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 0.78% from the last closing price in January, 2023. This potential increase is based on a high estimate of kr1200.00 and a low estimate of kr540.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.
0.78% Upside
Novo Nordisk A/S Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Novo Nordisk A/S's Price has seen an increase, rising from kr376.90 to kr477.23. This represents a growth of 26.62%. For the next year, 0 analysts project Novo Nordisk A/S's Fair Value to drop by 11.79%, reaching kr420.96. By 2030, professionals believe that Novo Nordisk A/S's Fair Value will decrease by 10.68%, reaching kr426.28 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | $179.95 | 12.63% |
| ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | CHF384.23 | 24.32% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$32.98 | $44.13 | 59.64% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.84 | $99.57 | 11.49% |
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.14k | £153.20 | -98.60% |
Novo Nordisk A/S Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Novo Nordisk A/S's Revenue has seen an increase, rising from kr122.02B to kr140.80B. This represents a growth of 15.39%. For the next year, 0 analysts project Novo Nordisk A/S's Revenue to drop by 7.85%, reaching kr129.74B. By 2030, professionals believe that Novo Nordisk A/S's Revenue will decrease by 7.29%, reaching kr130.53B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$97.47 | $124.05 | 28.24% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$59.16 | $80.99 | 40.30% |
Novo Nordisk A/S Dividend per Share Forecast for 2023 - 2025 - 2030
Novo Nordisk A/S's Dividend per Share has seen growth In the last two years, going from kr8.35 to kr10.40 – a gain of 24.55% According to 0 prominent analysts, Novo Nordisk A/S's Dividend per Share will fall by 11.08% in the next year, reaching kr9.25. By 2030, professionals believe that Novo Nordisk A/S's Dividend per Share will decrease by 10.07%, reaching kr9.35 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | 108.44€ | 20.72% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$266.86 | $268.00 | 4.17% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.97 | $90.05 | 7.54% |
Novo Nordisk A/S Free Cash Flow Forecast for 2023 - 2025 - 2030
Novo Nordisk A/S's Free Cash Flow has grown in the last two years, jumping from kr37.85B to kr48.67B – an increase of 28.57%. According to 0 major analysts, Novo Nordisk A/S's Free Cash Flow will fall by 11.74% in the next year, reaching kr42.95B. Professionals believe that By 2030, Novo Nordisk A/S's Free Cash Flow will fall to kr43.51B– a 10.60% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$74.85 | $87.30 | 17.57% |
| CSL Stock Forecast | CSL | Buy |
8
|
$254.88 | $231.47 | -11.31% |
| BSX Stock Forecast | Boston Scientific Corp | Outperform |
15
|
$53.81 | $52.51 | -7.08% |
Novo Nordisk A/S Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Net Income for Novo Nordisk A/S has grown by 22.61%, going from kr38.95B to kr47.76B. In the following year, 0 experts forecast Novo Nordisk A/S's Net Income will decrease by 10.37%, to kr42.81B. In 2030, professionals predict that Novo Nordisk A/S's Net Income will decrease by 9.46%, to kr43.24B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.53k | £16.95 | -98.95% |
| SHW Stock Forecast | Sherwin Williams | Outperform |
15
|
$256.21 | $248.50 | 2.26% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
46.32€ | 74.54€ | 63.00% |
Novo Nordisk A/S EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Novo Nordisk A/S's EBITDA has increased by 12.86%, going from kr56.31B to kr63.55B. In the next year, 0 analysts estimate that Novo Nordisk A/S's EBITDA will decrease by 6.51%, reaching kr59.42B. According to professional forecasts, in 2030, Novo Nordisk A/S's EBITDA will decrease by 6.07%, reaching kr59.69B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | ¥0.00 | 35.30% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$255.02 | $322.44 | 27.44% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥4.08k | ¥0.00 | 7.84% |
Novo Nordisk A/S EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Novo Nordisk A/S's EBIT has grown, increasing from kr52.48B to kr59.34B – an increase of 13.07%. According to 0 analysts, Novo Nordisk A/S's EBIT will fall by 6.69% in the next year, reaching kr55.37B. Professionals believe that By 2030, Novo Nordisk A/S's EBIT will fall to kr55.64B – a 6.24% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| PPG Stock Forecast | PPG Industries Inc | Outperform |
13
|
$132.05 | $138.33 | 6.78% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$170.77 | $244.18 | 46.98% |
| HZNP Stock Forecast | Horizon Therapeutics Public | Buy |
16
|
$113.00 | $0.00 | 23.89% |
Novo Nordisk A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Novo Nordisk A/S's EPS has seen an increase, rising from kr16.38 to kr20.74. This represents a growth of 26.62%. For the next year, 0 analysts project Novo Nordisk A/S's EPS to drop by 11.79%, reaching kr18.29. By 2030, professionals believe that Novo Nordisk A/S's EPS will decrease by 10.68%, reaching kr18.53 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| IPN Stock Forecast | Ipsen | Hold |
17
|
102.20€ | 110.44€ | 5.68% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
18
|
Rp4.27k | Rp5.47k | 15.97% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
12.21€ | 27.25€ | 73.63% |